Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies Post author: Post published:March 18, 2024 Post category:uncategorized Immunome signs deal to use Arrayjet platform in its in-house screening operations. You Might Also Like Frequent salt addition at the table increases gastric cancer risk by 41% May 10, 2024 FAME-3 study reveals similar outcomes for CABG and PCI in severe triple-vessel heart disease March 31, 2025 New virus diagnosis device gives lab-quality results within just three minutes November 2, 2023
FAME-3 study reveals similar outcomes for CABG and PCI in severe triple-vessel heart disease March 31, 2025